期刊
MOVEMENT DISORDERS
卷 37, 期 8, 页码 1612-1623出版社
WILEY
DOI: 10.1002/mds.29122
关键词
Parkinson's; type 2 diabetes; disease progression; cognitive impairment
资金
- Parkinson's UK
- National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network
- National Institute for Health Research University College London (UCL) Hospitals Biomedical Research Centre
- Edmond J. Safra Philanthropic Foundation
In this study, the influence of type 2 diabetes on disease progression in Parkinson's disease was investigated. The results showed that patients with type 2 diabetes had more severe motor and nonmotor symptoms, were more likely to experience loss of independence and depression, and had faster motor symptom progression, worse mood symptoms, and higher risk of gait impairment and mild cognitive impairment compared to patients without type 2 diabetes.
Background Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson's disease (PD), but its effect on disease progression is not well understood. Objective The aim of this study was to investigate the influence of T2DM on aspects of disease progression in PD. Methods We analyzed data from the Tracking Parkinson's study to examine the effects of comorbid T2DM on PD progression and quality of life by comparing symptom severity scores assessing a range of motor and nonmotor symptoms. Results We identified 167 (8.7%) patients with PD and T2DM (PD + T2DM) and 1763 (91.3%) patients with PD without T2DM (PD). After controlling for confounders, patients with T2DM had more severe motor symptoms, as assessed by Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III (25.8 [0.9] vs. 22.5 [0.3] P = 0.002), and nonmotor symptoms, as assessed by Non-Motor Symptoms Scale total (38.4 [2.5] vs. 31.8 [0.7] P < 0.001), and were significantly more likely to report loss of independence (odds ratio, 2.08; 95% confidence interval [CI]: 1.34-3.25; P = 0.001) and depression (odds ratio, 1.62; CI: 1.10-2.39; P = 0.015). Furthermore, over time, patients with T2DM had significantly faster motor symptom progression (P = 0.012), developed worse mood symptoms (P = 0.041), and were more likely to develop substantial gait impairment (hazard ratio, 1.55; CI: 1.07-2.23; P = 0.020) and mild cognitive impairment (hazard ratio, 1.7; CI: 1.24-2.51; P = 0.002) compared with the PD group. Conclusions In the largest study to date, T2DM is associated with faster disease progression in Parkinson's, highlighting an interaction between these two diseases. Because it is a potentially modifiable metabolic state, with multiple peripheral and central targets for intervention, it may represent a target for alleviating parkinsonian symptoms and slowing progression to disability and dementia. (c) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据